To evaluate the clinical relevance of the study, we applied Kaplan-Meier survival analysis and found that patients with breast or ovarian cancer with high expression of FANCD2 and XRCC4 had poorer overall survival than those with low expression of FANCD2 and XRCC4 (Supplemental Figure 6). This evidence concerns the gene XRCC4 and ovarian cancer.